New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAHK-Cu vs AOD-9604

AHK-Cu vs AOD-9604

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
AHK-Cu
Fat Loss & Metabolic
AOD-9604
Summary
AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
Half-Life
Hours (topical, variable by formulation)
30-45 minutes injectable; longer with nasal spray formulation
Admin Route
Topical, Scalp application, Subcutaneous (research)
SubQ, Intranasal, Oral
Research
Typical Dose
0.01–0.1% concentration
300-600 mcg
Frequency
Once or twice daily
Once daily
Key Benefits
  • Stimulates hair follicle growth and reduces shedding
  • Increases dermal papilla cell proliferation
  • Promotes wound healing and skin regeneration
  • Antioxidant protection via superoxide dismutase activation
  • Improves skin elasticity and firmness
  • Supports collagen and elastin production
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
Side Effects
  • Generally well-tolerated topically
  • Mild scalp irritation or redness in sensitive individuals
  • Possible temporary hair shedding phase at treatment initiation
  • Copper accumulation with excessive systemic use (rare)
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
Stacks With